Skip to main content
. Author manuscript; available in PMC: 2016 Nov 7.
Published in final edited form as: Int J Cardiol. 2013 Nov 25;170(3):426–433. doi: 10.1016/j.ijcard.2013.11.034

Table 1.

Characteristics of the study participants.

Parameter Controls Autograft Mechanical Stentless bio Stented bio p
n 9 7 9 8 14
Sex (females/males) 1/8 2/5 0/9 2/6 4/10
Age (years) 55 ± 16 47 ± 17 61 ± 11 62 ± 20 77 ± 4 <0.001*
Native valvular lesion Stenosis (n = 3), regurgitation (n = 1), mixed (n = 3) Stenosis (n = 3), regurgitation (n = 5), mixed (n = 1) Stenosis (n = 5), regurgitation (n = 3) Stenosis (n = 7), regurgitation (n = 2), mixed (n = 5)
Time since valve surgery [years] 6.0 ± 4.2 7.9 ± 3.6 2.7 ± 4.8 3.6 ± 2.6 0.014*
Labeled valve size 24.3 ± 2.5 26.0 ± 1.5 23.6 ± 2.0 0.029*
Orifice area [cm2] 4.0 ± 0.8 4.6 ± 0.9 1.8 ± 0.5 2.0 ± 0.5 1.5 ± 0.4 <0.001*
Orifice area index [cm2/m2] 2.0 ± 0.4 2.3 ± 0.4 0.9 ± 0.2 1.1 ± 0.3 0.8 ± 0.2 <0.001*
Prosthetic types Only bileaflet valves. Levibio ATS (n = 1), Sorin Carbomedics (n = 1), Medtronic Advantage (n = 1), St. Jude Regent (n = 6) Porcine: Vascutek Elan (n = 1), Shelhigh (n = 3); St. Jude Toronto (n = 1); bovine: Sorin Freedom Solo (n = 2); Medtronic Freestyle (n = 1) Porcine: Medtronic Hancock (n = 6), Labcore (n = 1); bovine: Edwards Perimount (n = 3), Sorin Mitroflow (n = 2), unknown (n = 2)
LV end diastolic volume [ml] 140 ± 41 176 ± 34 186 ± 98 165 ± 64 147 ± 58 0.459
LV stroke volume [ml] 92 ± 28 98 ± 22 76 ± 51 98 ± 40 84 ± 31 0.585
LV ejection fraction [%] 66 ± 6 57 ± 13 50 ± 14 60 ± 10 59 ± 11 0.049*
Aortic diameter [mm] 31 ± 5 37 ± 4 40 ± 8 37 ± 7 38 ± 4 0.009*

Results are given as frequencies or as mean ± SD. The p-value relates to the Kruskal–Wallis multiple group comparison. Further inter-study relations are outlined in the text.